CD200-expressing human basal cell carcinoma cells initiate tumor growth

Chantal S. Colmont, Antisar BenKetah, Simon H. Reed, Nga V. Hawk, William G. Telford, Manabu Ohyama, Mark C. Udey, Carole L. Yee, Jonathan C. Vogel, Girish K. Patel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growthwith inward differentiation along hair follicle lineages. Most BCC cells express the transcription factor KLF4 and are committed to terminal differentiation. A small CD200+ CD45- BCC subpopulation that represents 1.63 ± 1.11% of all BCC cells resides in small clusters at the tumor periphery. By using reproducible in vivo xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.5 million unsorted BCC cells. The CD200+ CD45- BCC subpopulation recreated BCC tumor growth in vivo with typical histological architecture and expression of sonic hedgehog-regulated genes. Reproducible in vivo BCC growth was achievedwith as few as 10,000 CD200+ CD45- cells, representing ̃1,500-fold enrichment. CD200- CD45- BCC cells were unable to form tumors. These findings establish a platform to study the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently available anti-CD200 therapy be considered, either asmonotherapy or an adjunct to Smoothened antagonists, in the treatment of inoperable BCC.

Original languageEnglish
Pages (from-to)1434-1439
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number4
DOIs
Publication statusPublished - 2013 Jan 22

Fingerprint

Basal Cell Carcinoma
Growth
Neoplasms
Neoplastic Stem Cells
Hair Follicle
Medical Genetics
Fluorescence Microscopy
Heterografts
Transcription Factors

ASJC Scopus subject areas

  • General

Cite this

Colmont, C. S., BenKetah, A., Reed, S. H., Hawk, N. V., Telford, W. G., Ohyama, M., ... Patel, G. K. (2013). CD200-expressing human basal cell carcinoma cells initiate tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 110(4), 1434-1439. https://doi.org/10.1073/pnas.1211655110

CD200-expressing human basal cell carcinoma cells initiate tumor growth. / Colmont, Chantal S.; BenKetah, Antisar; Reed, Simon H.; Hawk, Nga V.; Telford, William G.; Ohyama, Manabu; Udey, Mark C.; Yee, Carole L.; Vogel, Jonathan C.; Patel, Girish K.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 4, 22.01.2013, p. 1434-1439.

Research output: Contribution to journalArticle

Colmont, CS, BenKetah, A, Reed, SH, Hawk, NV, Telford, WG, Ohyama, M, Udey, MC, Yee, CL, Vogel, JC & Patel, GK 2013, 'CD200-expressing human basal cell carcinoma cells initiate tumor growth', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 4, pp. 1434-1439. https://doi.org/10.1073/pnas.1211655110
Colmont, Chantal S. ; BenKetah, Antisar ; Reed, Simon H. ; Hawk, Nga V. ; Telford, William G. ; Ohyama, Manabu ; Udey, Mark C. ; Yee, Carole L. ; Vogel, Jonathan C. ; Patel, Girish K. / CD200-expressing human basal cell carcinoma cells initiate tumor growth. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 4. pp. 1434-1439.
@article{79ee9e7845274e359cb5f789cb360114,
title = "CD200-expressing human basal cell carcinoma cells initiate tumor growth",
abstract = "Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growthwith inward differentiation along hair follicle lineages. Most BCC cells express the transcription factor KLF4 and are committed to terminal differentiation. A small CD200+ CD45- BCC subpopulation that represents 1.63 ± 1.11{\%} of all BCC cells resides in small clusters at the tumor periphery. By using reproducible in vivo xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.5 million unsorted BCC cells. The CD200+ CD45- BCC subpopulation recreated BCC tumor growth in vivo with typical histological architecture and expression of sonic hedgehog-regulated genes. Reproducible in vivo BCC growth was achievedwith as few as 10,000 CD200+ CD45- cells, representing ̃1,500-fold enrichment. CD200- CD45- BCC cells were unable to form tumors. These findings establish a platform to study the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently available anti-CD200 therapy be considered, either asmonotherapy or an adjunct to Smoothened antagonists, in the treatment of inoperable BCC.",
author = "Colmont, {Chantal S.} and Antisar BenKetah and Reed, {Simon H.} and Hawk, {Nga V.} and Telford, {William G.} and Manabu Ohyama and Udey, {Mark C.} and Yee, {Carole L.} and Vogel, {Jonathan C.} and Patel, {Girish K.}",
year = "2013",
month = "1",
day = "22",
doi = "10.1073/pnas.1211655110",
language = "English",
volume = "110",
pages = "1434--1439",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "4",

}

TY - JOUR

T1 - CD200-expressing human basal cell carcinoma cells initiate tumor growth

AU - Colmont, Chantal S.

AU - BenKetah, Antisar

AU - Reed, Simon H.

AU - Hawk, Nga V.

AU - Telford, William G.

AU - Ohyama, Manabu

AU - Udey, Mark C.

AU - Yee, Carole L.

AU - Vogel, Jonathan C.

AU - Patel, Girish K.

PY - 2013/1/22

Y1 - 2013/1/22

N2 - Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growthwith inward differentiation along hair follicle lineages. Most BCC cells express the transcription factor KLF4 and are committed to terminal differentiation. A small CD200+ CD45- BCC subpopulation that represents 1.63 ± 1.11% of all BCC cells resides in small clusters at the tumor periphery. By using reproducible in vivo xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.5 million unsorted BCC cells. The CD200+ CD45- BCC subpopulation recreated BCC tumor growth in vivo with typical histological architecture and expression of sonic hedgehog-regulated genes. Reproducible in vivo BCC growth was achievedwith as few as 10,000 CD200+ CD45- cells, representing ̃1,500-fold enrichment. CD200- CD45- BCC cells were unable to form tumors. These findings establish a platform to study the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently available anti-CD200 therapy be considered, either asmonotherapy or an adjunct to Smoothened antagonists, in the treatment of inoperable BCC.

AB - Smoothened antagonists directly target the genetic basis of human basal cell carcinoma (BCC), the most common of all cancers. These drugs inhibit BCC growth, but they are not curative. Although BCC cells are monomorphic, immunofluorescence microscopy reveals a complex hierarchical pattern of growthwith inward differentiation along hair follicle lineages. Most BCC cells express the transcription factor KLF4 and are committed to terminal differentiation. A small CD200+ CD45- BCC subpopulation that represents 1.63 ± 1.11% of all BCC cells resides in small clusters at the tumor periphery. By using reproducible in vivo xenograft growth assays, we determined that tumor initiating cell frequencies approximate one per 1.5 million unsorted BCC cells. The CD200+ CD45- BCC subpopulation recreated BCC tumor growth in vivo with typical histological architecture and expression of sonic hedgehog-regulated genes. Reproducible in vivo BCC growth was achievedwith as few as 10,000 CD200+ CD45- cells, representing ̃1,500-fold enrichment. CD200- CD45- BCC cells were unable to form tumors. These findings establish a platform to study the effects of Smoothened antagonists on BCC tumor initiating cell and also suggest that currently available anti-CD200 therapy be considered, either asmonotherapy or an adjunct to Smoothened antagonists, in the treatment of inoperable BCC.

UR - http://www.scopus.com/inward/record.url?scp=84872873292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872873292&partnerID=8YFLogxK

U2 - 10.1073/pnas.1211655110

DO - 10.1073/pnas.1211655110

M3 - Article

C2 - 23292936

AN - SCOPUS:84872873292

VL - 110

SP - 1434

EP - 1439

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 4

ER -